Skip to main content
Erschienen in: World Journal of Urology 4/2020

28.05.2019 | Original Article

Accuracy of the preoperative PSA level for predicting clinically significant incidental transitional zone-prostate cancer before endoscopic enucleation of very large adenoma

verfasst von: Vincent Misraï, Marie Pasquie, Benoit Bordier, Julien Guillotreau, Alexandre Gryn, Julien Palasse, Eric Bruguière, Benjamin Pradere, Morgan Rouprêt, Kevin C. Zorn

Erschienen in: World Journal of Urology | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Objective

To analyse the accuracy of high preoperative PSA levels for predicting transitional zone incidental PCa (TZ-PCa) in men with very large prostates.

Materials and methods

Perioperative data from 375 consecutive patients who underwent endoscopic enucleation of the prostate (EEP) for benign prostatic obstruction between July 2013 and December 2018 were retrospectively reviewed. Patients were stratified into three groups according to the preoperative PSA level: low-PSA (< 4 ng/mL), intermediate-PSA (4 ≤ PSA < 10 ng/mL) and high-PSA (≥ 10 ng/mL). Men in each group were propensity score matched by age, 5α-reductase inhibitor (5-ARI) use, prostate volume and mpMRI. The TZ-PCa incidence rate was retrospectively compared by preoperative PSA level in a propensity score model including all predetermined variables.

Results

Age, prostate volume, 5-ARI use were similar between patient groups. The median PSA levels in the low-, intermediate- and high-PSA groups were 3 [2.3; 3.4], 6.6 [5.3; 8.1] and 12.7 [11; 16.7] ng/mL, respectively. The median prostate volume was > 100 grams in all groups (108, 105 and 120 cc, respectively). The T1a-Gleason 6 incidental TZ-PCa rate was statistically comparable between the three groups (3.4, 5.1 and 8.6% in the low-, intermediate- and high-PSA groups, respectively). The detection rate of clinically significant TZ-PCa was low for preoperative PSA levels > 4 ng/mL (1.7%); with no difference between the intermediate- and high-PSA groups.

Conclusion

In men with large glands, the clinically significant incidental TZ-PCa detection rate was similar regardless of the preoperative PSA level stratum. Such details may help with patient counselling during BPH surgical management.
Literatur
1.
Zurück zum Zitat Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M et al (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 71:618–629CrossRef Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M et al (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 71:618–629CrossRef
4.
Zurück zum Zitat Herlemann A, Wegner K, Roosen A, Buchner A, Weinhold P, Bachmann A et al (2017) “Finding the needle in a haystack”: oncologic evaluation of patients treated for LUTS with holmium laser enucleation of the prostate (HoLEP) versus transurethral resection of the prostate (TURP). World J Urol 35:1777–1782CrossRef Herlemann A, Wegner K, Roosen A, Buchner A, Weinhold P, Bachmann A et al (2017) “Finding the needle in a haystack”: oncologic evaluation of patients treated for LUTS with holmium laser enucleation of the prostate (HoLEP) versus transurethral resection of the prostate (TURP). World J Urol 35:1777–1782CrossRef
5.
Zurück zum Zitat Bhojani N, Boris RS, Monn MF, Mandeville JA, Lingeman JE (2015) Coexisting prostate cancer found at the time of holmium laser enucleation of the prostate for benign prostatic hyperplasia: predicting its presence and grade in analyzed tissue. J Endourol 29:41–46CrossRef Bhojani N, Boris RS, Monn MF, Mandeville JA, Lingeman JE (2015) Coexisting prostate cancer found at the time of holmium laser enucleation of the prostate for benign prostatic hyperplasia: predicting its presence and grade in analyzed tissue. J Endourol 29:41–46CrossRef
6.
Zurück zum Zitat Elkoushy MA, Elshal AM, Elhilali MM (2015) Incidental prostate cancer diagnosis during holmium laser enucleation: assessment of predictors, survival, and disease progression. Urology 86:552–557CrossRef Elkoushy MA, Elshal AM, Elhilali MM (2015) Incidental prostate cancer diagnosis during holmium laser enucleation: assessment of predictors, survival, and disease progression. Urology 86:552–557CrossRef
7.
Zurück zum Zitat Roobol MJ (2014) Words of wisdom. Re: PSA density improves prediction of prostate cancer. Eur Urol 66:964–965CrossRef Roobol MJ (2014) Words of wisdom. Re: PSA density improves prediction of prostate cancer. Eur Urol 66:964–965CrossRef
8.
Zurück zum Zitat Mochtar CA, Kiemeney LM, van Riemsdijk MM, Barnett GS, Laguna MP, Debruyne FMJ et al (2003) Prostate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia. Eur Urol 44:695–700CrossRef Mochtar CA, Kiemeney LM, van Riemsdijk MM, Barnett GS, Laguna MP, Debruyne FMJ et al (2003) Prostate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia. Eur Urol 44:695–700CrossRef
9.
Zurück zum Zitat Pinsky PF, Kramer BS, Crawford ED, Grubb RL, Urban DA, Andriole GL et al (2006) Prostate volume and prostate-specific antigen levels in men enrolled in a large screening trial. Urology 68:352–356CrossRef Pinsky PF, Kramer BS, Crawford ED, Grubb RL, Urban DA, Andriole GL et al (2006) Prostate volume and prostate-specific antigen levels in men enrolled in a large screening trial. Urology 68:352–356CrossRef
10.
Zurück zum Zitat Peyronnet B, Robert G, Comat V, Rouprêt M, Gomez-Sancha F, Cornu J-N et al (2017) Learning curves and perioperative outcomes after endoscopic enucleation of the prostate: a comparison between GreenLight 532 nm and holmium lasers. World J Urol 35:973–983CrossRef Peyronnet B, Robert G, Comat V, Rouprêt M, Gomez-Sancha F, Cornu J-N et al (2017) Learning curves and perioperative outcomes after endoscopic enucleation of the prostate: a comparison between GreenLight 532 nm and holmium lasers. World J Urol 35:973–983CrossRef
11.
Zurück zum Zitat Rosenbaum PR, Rubin DB (1985) Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat 39:33–38 Rosenbaum PR, Rubin DB (1985) Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat 39:33–38
12.
Zurück zum Zitat Rosenbaum PR, Rubin DB (1983) The central role of the propensity score in observational studies for causal effects. Biometrika 70:41–55CrossRef Rosenbaum PR, Rubin DB (1983) The central role of the propensity score in observational studies for causal effects. Biometrika 70:41–55CrossRef
13.
Zurück zum Zitat Wallerstedt A, Strom P, Gronberg H, Nordstrom T, Eklund M (2018) Risk of prostate cancer in men treated with 5α-reductase inhibitors-A large population-based prospective study. J Natl Cancer Inst 110:1216–1221CrossRef Wallerstedt A, Strom P, Gronberg H, Nordstrom T, Eklund M (2018) Risk of prostate cancer in men treated with 5α-reductase inhibitors-A large population-based prospective study. J Natl Cancer Inst 110:1216–1221CrossRef
14.
Zurück zum Zitat Ohwaki K, Endo F, Shimbo M, Fujisaki A, Hattori K (2017) Comorbidities as predictors of incidental prostate cancer after Holmium laser enucleation of the prostate: diabetes and high-risk cancer. Aging Male Off J Int Soc Study Aging Male 20:257–260CrossRef Ohwaki K, Endo F, Shimbo M, Fujisaki A, Hattori K (2017) Comorbidities as predictors of incidental prostate cancer after Holmium laser enucleation of the prostate: diabetes and high-risk cancer. Aging Male Off J Int Soc Study Aging Male 20:257–260CrossRef
15.
Zurück zum Zitat Ho D, Imai K, King G, Stuart EA (2011) MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Softw 42:1–28CrossRef Ho D, Imai K, King G, Stuart EA (2011) MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Softw 42:1–28CrossRef
16.
Zurück zum Zitat Voigt S, Hüttig F, Koch R, Propping S, Propping C, Grimm M-O et al (2011) Risk factors for incidental prostate cancer-who should not undergo vaporization of the prostate for benign prostate hyperplasia? Prostate 71:1325–1331PubMed Voigt S, Hüttig F, Koch R, Propping S, Propping C, Grimm M-O et al (2011) Risk factors for incidental prostate cancer-who should not undergo vaporization of the prostate for benign prostate hyperplasia? Prostate 71:1325–1331PubMed
17.
Zurück zum Zitat Helfand BT, Anderson CB, Fought A, Kim DY, Vyas A, McVary KT (2009) Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia. Urology 74:177–183CrossRef Helfand BT, Anderson CB, Fought A, Kim DY, Vyas A, McVary KT (2009) Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia. Urology 74:177–183CrossRef
18.
Zurück zum Zitat Rosenhammer B, Lausenmeyer EM, Mayr R, Burger M, Eichelberg C (2018) HoLEP provides a higher prostate cancer detection rate compared to bipolar TURP: a matched-pair analysis. World J Urol 36:2035–2041CrossRef Rosenhammer B, Lausenmeyer EM, Mayr R, Burger M, Eichelberg C (2018) HoLEP provides a higher prostate cancer detection rate compared to bipolar TURP: a matched-pair analysis. World J Urol 36:2035–2041CrossRef
19.
Zurück zum Zitat Naspro R, Freschi M, Salonia A, Guazzoni G, Girolamo V, Colombo R et al (2004) Holmium laser enucleation versus transurethral resection of the prostate. Are histological findings comparable? J Urol 171:1203–1206CrossRef Naspro R, Freschi M, Salonia A, Guazzoni G, Girolamo V, Colombo R et al (2004) Holmium laser enucleation versus transurethral resection of the prostate. Are histological findings comparable? J Urol 171:1203–1206CrossRef
20.
Zurück zum Zitat Gudmundsson J, Sigurdsson JK, Stefansdottir L, Agnarsson BA, Isaksson HJ, Stefansson OA et al (2018) Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA. Nat Commun 9:4568CrossRef Gudmundsson J, Sigurdsson JK, Stefansdottir L, Agnarsson BA, Isaksson HJ, Stefansson OA et al (2018) Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA. Nat Commun 9:4568CrossRef
21.
Zurück zum Zitat Stephan C, Stroebel G, Heinau M, Lenz A, Roemer A, Lein M et al (2005) The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL. Cancer 104:993–1003CrossRef Stephan C, Stroebel G, Heinau M, Lenz A, Roemer A, Lein M et al (2005) The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL. Cancer 104:993–1003CrossRef
22.
Zurück zum Zitat Lee H, Hwang SI, Lee HJ, Byun S-S, Lee SE, Hong SK (2018) Diagnostic performance of diffusion-weighted imaging for prostate cancer: peripheral zone versus transition zone. PLoS One 13:e0199636CrossRef Lee H, Hwang SI, Lee HJ, Byun S-S, Lee SE, Hong SK (2018) Diagnostic performance of diffusion-weighted imaging for prostate cancer: peripheral zone versus transition zone. PLoS One 13:e0199636CrossRef
Metadaten
Titel
Accuracy of the preoperative PSA level for predicting clinically significant incidental transitional zone-prostate cancer before endoscopic enucleation of very large adenoma
verfasst von
Vincent Misraï
Marie Pasquie
Benoit Bordier
Julien Guillotreau
Alexandre Gryn
Julien Palasse
Eric Bruguière
Benjamin Pradere
Morgan Rouprêt
Kevin C. Zorn
Publikationsdatum
28.05.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 4/2020
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-019-02823-6

Weitere Artikel der Ausgabe 4/2020

World Journal of Urology 4/2020 Zur Ausgabe

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.